EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia



CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia



Blood 98(1): 181-186, July 1



CD38 is a transmembrane glycoprotein expressed on the surface of leukemic cells in a significant percentage of patients with B-cell chronic lymphocytic leukemia (B-CLL). A recent study suggested that CD38 expression has prognostic value in CLL. Peripheral blood samples from 218 patients with B-CLL were analyzed by flow cytometry for CD38 expression on CD5/19(+) leukemic cells. Various patient characteristics were studied including age, sex, Rai and Binet stages, splenomegaly, hepatomegaly, hemoglobin (Hgb) level, beta-2 microglobulin (beta2M) level in the serum, number of nodal sites involved with disease, and length of survival. The Kaplan-Meier method was used to construct survival curves, and the log-rank statistic was used to compare these curves. CD38 was expressed in 20% or more of leukemic cells in 43% of the patients. Patients with high CD38 expression (20% or more) had significantly shorter survival times (P =.00005). Multivariate analyses showed that CD38 expression is an important prognostic factor associated with high incidence of lymph node involvement (P =.004), lower hemoglobin level (P =.001), hepatomegaly (P =.05), and high beta2M level (P =.00005). CD38 expression identified a group of patients with aggressive disease that was considered by Rai staging to be early-stage disease (Rai stages 0-II). Patients with CD38(+) samples have significantly aggressive disease regardless of their clinical stage. Measurement of CD38 expression by flow cytometry should become a routine test in the evaluation of patients with CLL.

(PDF emailed within 0-6 h: $19.90)

Accession: 010263044

Download citation: RISBibTeXText

PMID: 11418478

DOI: 10.1182/blood.V98.1.181



Related references

The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia. Journal of Biological Regulators and Homeostatic Agents 18(3-4): 340-346, 2004

The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia. Journal of Biological Regulators and Homeostatic Agents 18(3-4): 340-346, 2005

The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leukemia & Lymphoma 45(3): 455-462, 2004

Is assessment of surface CD38 expression worthwhile as a prognostic factor in chronic lymphocytic leukemia patients?. Hematology 13(1): 24-27, 2008

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99(3): 1023-1029, 2002

CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression. Cytometry. Part B, Clinical Cytometry 70(3): 136-141, 2006

Gene Expression Profiling in CD38+ Versus CD38- B Cell Chronic Lymphocytic Leukemia. Blood 100(11): Abstract No 1480, November 16, 2002

CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16(1): 30-35, 2002

CD38 variation as a prognostic factor in chronic lymphocytic leukemia. Leukemia & Lymphoma 55(1): 191-194, 2014

Relationship between cell surface expression of CD38 and of vascular endothelial growth factor in B-cell chronic lymphocytic leukemia. Leukemia Research 28(11): 1239-1240, 2004

CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. British Journal of Haematology 116(1): 142-150, January, 2002

The Prognostic Significance of Combined Expression of ZAP-70 and CD38 in Chronic Lymphocytic Leukemia. Journal of the Egyptian National Cancer Institute 21(4): 287-297, 2009

CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia. Official Gazette of the United States Patent & Trademark Office Patents 1266(2), Jan 14, 2003